Scott D Taylor
Overview
Explore the profile of Scott D Taylor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shivers L, Goodyear J, Taylor S
Org Lett
. 2025 Jan;
27(1):450-454.
PMID: 39745062
The first total synthesis of cyclic depsipeptide antibiotic LL-A0341β (LL) is described. The configuration of the β-methyltryptophan (β-MeTrp) residue was established by preparing all four stereoisomers of Fmoc-β-MeTrp which were...
2.
Goodyear J, Diamandas M, Moreira R, Taylor S
ACS Infect Dis
. 2024 Dec;
11(1):226-237.
PMID: 39716400
The calcium-dependent antibiotics (CDAs) are a group of seven closely related membrane-active cyclic lipopeptide antibiotics (cLPAs) first isolated in the early 1980s from the fermentation broth of . Their target...
3.
Chin J, Tan Z, Chan L, Ruffin F, Parmar R, Ahn R, et al.
PNAS Nexus
. 2024 May;
3(5):pgae185.
PMID: 38779114
Methicillin-resistant (MRSA) bacteremia is a common and life-threatening infection that imposes up to 30% mortality even when appropriate therapy is used. Despite in vitro efficacy determined by minimum inhibitory concentration...
4.
Creixell M, Taylor S, Gerritsen J, Bae S, Jiang M, Augustin T, et al.
bioRxiv
. 2023 Nov;
PMID: 37961516
Receptor tyrosine kinase (RTK)-targeted therapies are often effective but invariably limited by drug resistance. A major mechanism of acquired resistance involves "bypass" switching to alternative pathways driven by non-targeted RTKs...
5.
Orcutt-Jahns B, Emmel P, Snyder E, Taylor S, Meyer A
Sci Signal
. 2023 Oct;
16(807):eadg0699.
PMID: 37847758
The cytokine interleukin-2 (IL-2) has the potential to treat autoimmune disease but is limited by its modest specificity toward immunosuppressive regulatory T (T) cells. IL-2 receptors consist of combinations of...
6.
Moreira R, Taylor S
Org Biomol Chem
. 2022 Sep;
20(47):9319-9329.
PMID: 36129316
Daptomycin is an important clinical antibiotic for which resistance is rising. Daptomycin resistant strains of often have increased 1,2-diacyl--3-[phospho-1-(3-lysyl(1-glycerol))] (lysyl-PG) and mutations to the proteins directly involved in the synthesis...
7.
Noden M, Goodyear J, Taylor S
ACS Infect Dis
. 2022 Sep;
8(10):2073-2083.
PMID: 36083849
Paenibacterin A1 (PA1) is a broad-spectrum, cationic cyclic lipodepsipeptide antibiotic isolated from . In this study, the roles of the cationic residues and lipid tail length on the in vitro...
8.
Moreira R, Taylor S
ACS Infect Dis
. 2022 Aug;
8(9):1935-1947.
PMID: 36001599
A54145 factor D (A5D) is a cyclic lipopeptide antibiotic that shares several structural and mechanistic features with the clinically important antibiotic daptomycin, such as their requirement for calcium and phosphatidylglycerol...
9.
Miller J, Srinivasan Y, Dharmaraj N, Liu A, Nguyen P, Taylor S, et al.
J Am Chem Soc
. 2022 Jul;
144(28):12681-12689.
PMID: 35802879
Proteins that self-assemble into enclosed polyhedral cages, both naturally and by design, are garnering attention for their prospective utility in the fields of medicine and biotechnology. Notably, their potential for...
10.
Moreira R, Taylor S
ACS Infect Dis
. 2022 Jul;
8(8):1674-1686.
PMID: 35793519
Daptomycin is a clinical antibiotic used to treat serious infections caused by Gram-positive bacteria. Although there is debate about the action mechanism of daptomycin, it is known that daptomycin requires...